Lee Jungsoo, Kim Taeyeong, Cheon Sang-Jin, Kim Jinmi, Kim Hoon-Soo, Kim Byung-Soo, Kim Moon-Bum, Ko Hyun-Chang
Department of Dermatology, Pusan National University Yangsan Hospital, Yangsan, Korea.
Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Korea.
Ann Dermatol. 2023 Apr;35(2):124-131. doi: 10.5021/ad.22.114.
Topical medications play a crucial role in the treatment of atopic dermatitis (AD). Topical corticosteroids (TCSs) remain the main treatment of choice and topical antibiotics have also been used. However, with the new topical calcineurin inhibitors (TCIs), the prescription patterns of topical agents have changed over time.
To characterize the prescription patterns of topical medications in Korean patients with AD.
We investigated topical medications prescribed to Korean patients with AD using the National Health Insurance Sharing System (NHISS) database over a 14-year period (2002~2015). Additionally, the potency of prescribed TCSs was compared with AD and psoriasis patients.
The annual prescription of TCSs showed a slightly decreasing trend without significant change. In particular, in terms of steroid class, prescription of moderate-to-low potency TCSs were increased and the use of high potency TCSs were decreased. TCSs were the most commonly prescribed topical medications for AD. Tertiary hospitals had a higher prescription rate for TCIs than secondary or primary hospitals (16.2%, 3.1%, and 1.9%, respectively). Additionally, dermatologists prescribed TCIs more frequently than pediatricians and internists (4.3%, 1.2%, and 0.6%, respectively). Among TCSs, Class 5 was prescribed the most (40.6%) followed by Class 7, 6, 4, 3, 1, and 2. When we compared the potency of TCSs prescribed for AD with psoriasis patients, moderate-to-low-potency TCSs were more commonly prescribed in AD.
Prescription patterns of topical medications had changed from 2002 to 2015 and differed according to the type of institution and specialty of the physician.
局部用药在特应性皮炎(AD)的治疗中起着关键作用。局部糖皮质激素(TCSs)仍然是主要的治疗选择,局部抗生素也已被使用。然而,随着新型局部钙调神经磷酸酶抑制剂(TCIs)的出现,局部用药的处方模式随时间发生了变化。
描述韩国AD患者局部用药的处方模式。
我们使用国家健康保险共享系统(NHISS)数据库,对14年期间(2002年至2015年)韩国AD患者开具的局部用药进行了调查。此外,还比较了AD患者和银屑病患者所开具TCSs的效力。
TCSs的年处方量呈略有下降趋势,但无显著变化。特别是,从中度至低效TCSs的处方增加,高效TCSs的使用减少。TCSs是AD最常用的局部用药。三级医院TCIs的处方率高于二级或一级医院(分别为16.2%、3.1%和1.9%)。此外,皮肤科医生开具TCIs的频率高于儿科医生和内科医生(分别为4.3%、1.2%和0.6%)。在TCSs中,5类的处方最多(40.6%),其次是7类、6类、4类、3类、1类和2类。当我们比较AD患者和银屑病患者所开具TCSs的效力时,AD患者中更常开具中度至低效TCSs。
2002年至2015年期间,局部用药的处方模式发生了变化,并且因机构类型和医生专业不同而有所差异。